Bioavailability of Digoxin

Binnion, Peter F.; McDermott, Mark L.; Kalman, Sumner M.; Doherty, JamesE.; Bissett, JoeK.; Ratts, T.E.

doi:10.1016/s0140-6736(72)91976-9

Cited by 24 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The serum concentration-time curves produced in the fedstate experiment are different from those produced in the fasting experiment because of the known retardation of digoxin absorption due to feeding before administration of drug (White et al, 1971). These results are similar to, and serve as a model for, those found when different oral formulations of digoxin were tested (Doherty, 1968;Lindenbaum et al, 1971;Manninen et al, 1971;Binnion and McDermott, 1972;Hibble et al, 1972). Our data could be falsely interpreted to indicate differences in bioavailability with respect to both the extent and rate of drug absorption.…”

Section: Discussionsupporting

confidence: 84%

“…A number of recent studies have investigated the bioavailability of various types and brands of oral digoxin (Lindenbaum et al, 1971;Manninen et al, 1971;Binnion and McDermott, 1972;Hibble et al, 1972;Wagner et al, 1973). Bioavailability may be misjudged if inaccurate conclusions are drawn from comparative peak serum concentrations of drug.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics of Digoxin: Interpreting Bioavailability

Sanchez¹,

Sheiner²,

Halkin³

et al. 1973

BMJ

View full text Add to dashboard Cite

SummaryThree subjects were first given a digoxin tablet in the fasting state and subsequently received the same formulation in the fed state, to simulate a spurious oral bioavailability difference. As expected, when measured by peak serum digoxin concentration as well as by area under the serum digoxin concentration-time curve the bioavailability of digoxin appeared to be higher in the fasting state than in the fed state. However, when measured by cumulative five-day urinary excretion of digoxin bioavailability was identical in both conditions. This simple experiment illustrates the fact that the estimation of bioavailability is subject to considerable methodological error, of which the clinician must be aware when evaluating reports on drug bioavailability in general and of digoxin in particular.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Pharmacokinetics of Digoxin: Interpreting Bioavailability

Sanchez¹,

Sheiner²,

Halkin³

et al. 1973

BMJ

View full text Add to dashboard Cite

show abstract

“…The variation in bioavailability of digoxin from tablet dosage forms was recently reported (1)(2)(3)(4)(5). Such variations were also found in different lots of the formulated product made by the same manufacturer (1,6,7).…”

mentioning

confidence: 77%

“…Such variations were also found in different lots of the formulated product made by the same manufacturer (1,6,7). Several poorly absorbed preparations were reported (1)(2)(3)(4) to be therapeutically ineffective or associated with digoxin levels below the therapeutic range. The hydrophobicity and poor aqueous solubility of digoxin account to a significant degree for these variations.…”

mentioning

confidence: 99%

Influence of Dispersion Method on Dissolution Rate and Bioavailability of Digoxin from Triturations and Compressed Tablets II

Shah

Pytelewski

Eisen

et al. 1974

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…Marked differences in the bioavailability of digoxin from commercial tablet dosage forms have been reported (1)(2)(3)(4)(5)(6). Other reports (7, 8) indicated that digoxin is less than 100% absorbed from tablet dosage forms as compared to an oral solution or an intravenous injection.…”

mentioning

confidence: 99%